Placeholder Banner

BIO Statement Ahead of Chinese Vice Premier Visit to Washington

Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement ahead of Chinese Vice Premier Liu He's visit to Washington to participate in trade negotiations on Wednesday and Thursday. 

January 29, 2019
Media Contact
BIO logo

"President Trump has taken unprecedented measures to take on China – our largest trading partner – for its history of trade abuses. Beijing has long imposed unjustified restrictions on U.S. companies seeking to do business in and export to China, particularly with respect to agricultural products.

"With Chinese Vice Premier Liu He in Washington to participate in bilateral trade talks, the Trump administration should remain steadfast in pushing China towards structural reforms of its market. This means that any prospective trade deal with China cannot be based simply on a promise to buy more U.S. products. Such a bargain would fail to address the longstanding impediments that have contributed to the trade deficit with China.

"Any trade deal must require systemic change from China when it comes to U.S. agricultural exports. It’s time for the Chinese government to implement a predictable, timely, transparent and science-based decision-making process that facilitates trade and the importation of agricultural biotechnology products.

"Under China’s current opaque regulatory system for agriculture, Beijing arbitrarily dictates what technologies our farmers can use to address production challenges such as pests and drought. This month, Beijing approved only five of the 10 biotechnology crops seeking Chinese market access. Many of the still-unapproved products have languished in China’s regulatory process for more than six years – with no rational or legitimate scientific basis for the hold-up. 

"As we near the March 1 deadline for a trade deal, U.S. Trade Representative Robert Lighthizer, Treasury Secretary Steve Mnuchin and Commerce Secretary Wilbur Ross must be resolute and insist on a deal with enduring commitments and not only purchases of U.S. goods. Any trade deal lacking fundamental reform is inadequate and only will exacerbate the inequities in our existing trading relationship that President Trump rightly is trying to tackle."

According to a recent analysis, China’s delays in approving biotechnology crops have resulted in foregone U.S. economic growth of nearly 34,000 jobs, $7 billion in GDP, and $4.6 billion in wages.


Discover More
Washington, D.C. (June 24, 2020)—The Biotechnology Innovation Organization issued the following statement on today’s hearing on the Growing Climate Solutions Act: “The importance of today’s discussion cannot be understated. Climate change is a…
The U.S. Department of Agriculture (USDA) released today a modernized, science-based regulatory system for plant biotechnology aimed at maintaining oversight while driving innovation. Now government and industry must do more to build an informed and…
The Securities and Exchange Commission (SEC) has adopted regulatory changes to provide small public companies with a temporary exemption from Sarbanes-Oxley 404(b) compliance. 404(b) requires public companies to report on the internal controls they…